New cholesterol-lowering pill reduces bad cholesterol levels by almost 60%

Merck’s oral PCSK9 inhibitor Enlicitide produced large LDL-C reductions in a phase‑3, 52‑week randomized double‑blind trial of 303 adults with heterozygous familial hypercholesterolemia on background lipid therapy—mean LDL fell 58.2% at 24 weeks and 55.3% at 52 weeks versus an 8.7% rise on placebo; apolipoprotein B declined 48.2% and Lp(a) fell 24.7%. The drug was well tolerated with adverse‑event and discontinuation rates similar to placebo (77.7% vs 76.2% reporting any event; 2% vs 3% discontinued) and the results were published in JAMA. Ongoing trials will determine whether these potent lipid changes translate into fewer cardiovascular events and whether an oral PCSK9 option can broaden use beyond the HeFH population, a development with clear commercial and market-structure implications if outcomes are positive.

Analysis

Merck’s oral PCSK9 inhibitor Enlicitide produced large, durable lipid reductions in a 52‑week, phase‑3 randomized double‑blind trial of 303 adults with heterozygous familial hypercholesterolemia on background lipid therapy: mean LDL‑C fell 58.2% at 24 weeks and 55.3% at 52 weeks versus an 8.7% increase on placebo, with apolipoprotein B down 48.2% and Lp(a) down 24.7%; results were published in JAMA. The safety profile showed similar rates of any adverse event (77.7% Enlicitide vs 76.2% placebo) and similar discontinuation rates (2% vs 3%), indicating tolerability comparable to placebo in this population. These findings matter because an oral, once‑daily PCSK9 inhibitor that matches injectable agents on LDL‑C reduction could materially expand addressable patient populations and adherence versus current biologic PCSK9 therapies, but the clinical benefit for major adverse cardiovascular events (MACE) remains unproven. Ongoing outcome trials and broader high‑risk population studies are the critical next data points that will determine regulatory approvals, commercial labeling, pricing power, and the size of the market opportunity for MRK, and they are the principal near‑term catalysts and risks to monitor.

Key Decisions for Investors

• Consider a modest, catalyst‑driven long exposure to MRK to participate in upside potential from positive CV outcome and regulatory readouts, sizing positions to event risk
• Defer large, unhedged allocations until MACE outcome data demonstrate cardiovascular risk reduction and until regulatory approvals or broad labeling are secured
• Use hedged option strategies (e.g., limited‑risk call spreads) or small position exposure to capture upside from trial catalysts while limiting downside from regulatory or competitive setbacks
• Monitor near‑term indicators including cardiovascular outcome trial milestones, regulatory filings/briefings, pricing and reimbursement signals, and competitor PCSK9 developments as triggers to adjust positioning